Market Place
Sourcing Support
Changes in BBS-Bioactive Bone Substitutes Plc™s Management Team
06 Mar 2024 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Financial Statements Bulletin 2023
26 Feb 2024 //
GLOBENEWSWIRE
Drawdown of advance pursuant to financing arrangement between BBS and RiverFort
21 Feb 2024 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc has resolved on a share issue
31 Jan 2024 //
GLOBENEWSWIRE
Kimmo Tyni appointed as Product Director of BBS-Bioactive Bone Substitutes Plc
02 Jan 2024 //
GLOBENEWSWIRE
BBS-Bioactive Bone: Financial calendar and Annual General Meeting in 2024
27 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes: Merja Haikola appointed as Accountable Director
27 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone - Managers` Transactions “ Jarmo Halonen
19 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Oyj - Managers` Transactions “ Juliusz Rakowski
19 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes` rights issue raised gross proceeds of EUR 1.87M
18 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Managers` Transactions Oili Halonen
08 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Managers` Transactions Jarmo Halonen
08 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Managers` Transactions - Pekka Jalovaara
07 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Managers` Transactions - Pekka Jalovaara
04 Dec 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Managers` Transactions “ Pekka Jalovaara
30 Nov 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone: The Notified Body has approved the Companys quality system
25 Nov 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc publishes the Investor Memorandum
24 Nov 2023 //
GLOBENEWSWIRE
Juliusz Rakowski starts as CEO of BBS
15 Nov 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone: The company provides an update on the CE marking process
02 Nov 2023 //
GLOBENEWSWIRE
Resolutions of the Extraordinary General Meeting of BBS-Bioactive Bone
25 Oct 2023 //
GLOBENEWSWIRE
Resolutions of the General Meeting of BBS-Bioactive Bone Substitutes Plc
23 Oct 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc appoints Juliusz Rakowski as new CEO
03 Oct 2023 //
GLOBENEWSWIRE
Notice to the BBS-Bioactive Bone Substitutes Plc™s Extraordinary General Meeting
28 Sep 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone : Conversion of notes pursuant to financing arrangement
15 Sep 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes has resolved on a share issue
04 Sep 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes “ Inside information: The final report
31 Aug 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes: Half-Year Financial Report 1 Jan - 30 Jun 2023
25 Aug 2023 //
GLOBENEWSWIRE
Conversion of convertible notes pursuant to arrangement between BBS & Riverfort
17 Aug 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Oyj - Managers` Transactions “ Ahti Paananen
07 Aug 2023 //
GLOBENEWSWIRE
Conversion of convertible notes pursuant to financing arrangement between BBS and Riverfort
14 Jul 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes rights issue raised gross proceeds of EUR 1.84M
03 Jul 2023 //
GLOBENEWSWIRE
BBS: 57% of warrants 2-2022 (TO2) used for the subscription of shares
07 Jun 2023 //
GLOBENEWSWIRE
BBS: BBS arranges a rights offering of approximately maximum EUR 2.9 million
05 Jun 2023 //
GLOBENEWSWIRE
BBS Inside informationPositive decision received on the product classification
26 May 2023 //
GLOBENEWSWIRE
BBS: Conversion of convertible notes pursuant to financing arrangement
22 May 2023 //
GLOBENEWSWIRE
BBS: Subscription period for the second warrant series starts on 22 May 2023
19 May 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone: Fimea has conducted a regular periodic audit
17 May 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc has renewed a capital facility with RiverFort
31 Mar 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2023
30 Mar 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Inside information
27 Mar 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Annual Report for 2022 has been published
09 Mar 2023 //
GLOBENEWSWIRE
Notice to the BBS-Bioactive Bone Substitutes Plc Annual General Meeting
09 Mar 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes: Financial Statements Bulletin,1 Jan 31 Dec 2022
24 Feb 2023 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Applies for Delisting of Secondary Listing on Nasdaq
13 Feb 2023 //
GLOBENEWSWIRE
BBS`s Management Meets with Minister of Economic Affairs and MP
22 Dec 2022 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes: Financial calendar and Annual Meeting in 2023
14 Dec 2022 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Managers’ Transactions – Pekka Jalovaara
25 Aug 2022 //
GLOBENEWSWIRE
Changes in the BBS-Bioactive Bone Substitutes Plc’s Management Team
08 Aug 2022 //
GLOBENEWSWIRE
BBS: Trading on BBS` warrants begins on First North Growth Market Finland
28 Jun 2022 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes rights issue raised gross proceeds of EUR 3.5M
08 Jun 2022 //
GLOBENEWSWIRE
BBS publishes EU growth prospectus in connection to its EUR 4.5M rights issue
09 May 2022 //
GLOBENEWSWIRE
BBS arranges a rights issue of approx maximum 4.5 MEUR with additional warrants
06 May 2022 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes Plc: Decisions of the Annual General Meeting 2022
29 Apr 2022 //
GLOBENEWSWIRE
Invitation to Bbs-Bioactive Bone Substitutes Plc Annual General Meeting
05 Apr 2022 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes ANNUAL REPORT 2021
29 Mar 2022 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes: Decisions of Extraordinary General Meeting 2022
17 Mar 2022 //
GLOBENEWSWIRE
Invitation to Extraordinary General Meeting of Bbs-Bioactive Bone Substitutes
24 Feb 2022 //
GLOBENEWSWIRE
BBS-Bioactive Bone Substitutes: Financial Statements Review (unaudited)
24 Feb 2022 //
GLOBENEWSWIRE
